30 completed, 23 recruiting, 18 unknown, 11 terminated. 48 Phase 2, 43 Phase 1, 7 Phase 3, 2 Early Phase 1, 2 Not applicable.
Follow Advanced Melanoma: new trials by email Literature Review of Advanced Melanoma trials Research Report on Advanced Melanoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Optimizing Tumor-Infiltrating Lymphocyte (TIL) Harvest Site and Patient Selection With CD8-PET Imaging in Patients With Crefmirlimb, PET/CT imaging - Tumor Infiltrating Lymphocyte, CD8-PET | Not applicable | Not yet recruiting | M.D. Anderson Cancer Center | 6 | 2027-02-18 | 2026-09-15 |
| iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma iSCIB1+, Nivolumab & Ipilimumab, Placebo - Melanoma (Skin Cancer), Advanced Melanoma | Phase 3 | Not yet recruiting | Scancell Ltd | 550 | 2026-12-01 | 2026-09-11 |
| Multiple Adjunct Therapies to Improve Immunotherapy Treatment in Patients With Locally Advanced or Metastatic Melanoma or Advanced Hepatocellular Cancer Biospecimen Collection, Cholecalciferol, Computed Tomography - Advanced Hepatocellular Carcinoma, Advanced Melanoma | Phase 2 | Not yet recruiting | University of Southern California | 46 | 2026-11-01 | 2026-09-23 |
| MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. Immune Checkpoint Inhibitors - Melanoma, Advanced Melanoma | Phase 2 | Recruiting | Swiss Cancer Institute | 108 | 2026-10-12 | 2026-10-14 |
| Sitagliptin With Pembro in RCC and Melanoma Sitagliptin, Pembrolizumab - Advanced Renal Cell Carcinoma, Advanced Melanoma | Phase 1 | Recruiting | Fernando Maciel Barbosa | 64 | 2026-05-14 | 2026-07-30 |
| Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 Therapy Au-TMP, Fractionated Radiotherapy (RT), Toripalimab - Advanced Melanoma | Phase 1 | Recruiting | West China Hospital | 6 | 2026-04-28 | 2026-09-21 |
| Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study Biospecimen Collection, Immune Checkpoint Inhibitor - Advanced Biliary Tract Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma | Phase 4 | Recruiting | OHSU Knight Cancer Institute | 160 | 2026-04-24 | 2026-10-13 |
| ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab Nivolumab, Relatlimab, Ipilimumab - Metastatic Melanoma, Advanced Melanoma | Phase 2 | Recruiting | NYU Langone Health | 90 | 2026-04-13 | 2026-08-24 |
| A Phase II Trial of LM103 in Advanced Melanoma LM103 TILs Injection, Dacarbazine, temozolomide, paclitaxel, carboplatin/cisplatin - Advanced Melanoma | Phase 2 | Recruiting | Suzhou BlueHorse Therapeutics Co., Ltd. | 92 | 2025-12-16 | 2026-08-31 |
| A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma. LBL-024 for Injection, Toripalimab Injection - Advanced Melanoma | Phase 1 / Phase 2 | Recruiting | Nanjing Leads Biolabs Co.,Ltd | 280 | 2025-09-05 | 2026-10-21 |
| Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 OPM-101 - Advanced Melanoma | Phase 1 / Phase 2 | Not yet recruiting | Oncodesign Precision Medicine | 41 | 2025-09-01 | 2025-06-27 |
| A Clinical Study of BT02 for the Treatment of Patients With Advanced Malignant Melanoma BT02 - Advanced Melanoma, Advanced Solid Tumor | Phase 1 | Not yet recruiting | Biotroy Therapeutics | 58 | 2025-08-08 | 2025-08-06 |
| AB821 in Adult Participants With Locally Advanced or Metastatic Solid Tumors AB821 - Advanced Melanoma and Normal or Impaired, Advanced Melanoma | Phase 1 | Recruiting | Yale University | 50 | 2025-08-05 | 2026-06-16 |
| HS-IT101 Injection in the Treatment of Advanced Melanoma(FASTIL-Mela01) HS-IT101 Injection - Advanced Melanoma | Phase 1 | Completed | Hangzhou Huasai Biomedicine Co., Ltd. | 5 | 2025-07-10 | 2026-10-14 |
| Efficacy and Safety of Iparomlimab and Tuvonralimab Injection in Combination With Bevacizumab After Progression on Anti-PD-(L)1 Therapy in Advanced Melanoma: A Prospective, Single-Arm, Exploratory Clinical Study Iparomlimab and Tuvonralimab Injection plus Bevacizumab - PD-(L)1, CTLA-4 | Phase 4 | Not yet recruiting | Hebei Medical University Fourth Hospital | 40 | 2025-07-01 | 2025-06-04 |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. EIK1001, Pembrolizumab (KEYTRUDA® ) - Advanced Melanoma | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 740 | 2025-05-22 | 2026-10-06 |
| NY-ESO-1-redirected T Cells in Patients With Advanced Melanoma and Sarcoma NY-ESO-1 TCR redirected autologous T cell product, Low-dose irradiation, Non-myeloablative lymphodepleting chemotherapy - Advanced Melanoma, Melanoma Metastatic | Phase 1 | Recruiting | Centre Hospitalier Universitaire Vaudois | 9 | 2025-03-24 | 2026-05-15 |
| Outcomes of Nivolumab in Combination With Relatlimab in Patients With Advanced Melanoma in the Flatiron Database Nivolumab + Relatlimab, Nivolumab + Ipilimumab, Immunotherapy monotherapy - Advanced Melanoma | Completed | Bristol-Myers Squibb | 678 | 2024-11-29 | 2025-07-23 | |
| Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors Cytokine-induced memory-like natural killer cells, Relatilmab, Nivolumab - Advanced Melanoma, Metastatic Melanoma | Phase 1 | Suspended | Washington University School of Medicine | 33 | 2024-11-06 | 2026-09-22 |
| FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma Echopulse or Echopulse HD, PolyICLC - Advanced Melanoma | Early Phase 1 | Recruiting | University of Virginia | 11 | 2024-09-27 | 2025-11-20 |
Showing 20 of 101. Sign in to see all of them.
Melanoma (43) · Carcinoma, Renal Cell (6) · Lung Neoplasms (5) · Ovarian Neoplasms (5) · Neoplasm Metastasis (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (3) · Colorectal Neoplasms (3) · Neoplasms (3) · Skin Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Prostatic Neoplasms (2) · Squamous Cell Carcinoma of Head and Neck (2) · Carcinoma, Medullary (1) · Carcinoma, Transitional Cell (1)
Neoplasms (52) · Neoplasms by Site (51) · Neoplasms by Histologic Type (50) · Skin Diseases (45) · Skin and Connective Tissue Diseases (45) · Neoplasms, Germ Cell and Embryonal (43) · Neoplasms, Nerve Tissue (43) · Neuroectodermal Tumors (43) · Neuroendocrine Tumors (43) · Nevi and Melanomas (43) · Skin Neoplasms (40) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11)
Nivolumab (20) · pembrolizumab (16) · Ipilimumab (14) · Dacarbazine (6) · relatlimab (6) · Specimen Handling (5) · Opdualag (4) · Paclitaxel (4) · Temozolomide (4) · Carboplatin (3) · Injections (3) · toripalimab (3) · Axitinib (2) · Bevacizumab (2) · CTLA-4 Antigen (2)
Bristol-Myers Squibb (7) · M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (4) · Peking University Cancer Hospital & Institute (3) · Yale University (3) · Biocad (2) · H. Lee Moffitt Cancer Center and Research Institute (2) · Immunocore Ltd (2) · Merck Sharp & Dohme LLC (2) · Nanjing Leads Biolabs Co.,Ltd (2) · PrimeVax Immuno-Oncology Inc. (2) · Regeneron Pharmaceuticals (2) · Replimune, Inc. (2) · Shanghai Junshi Bioscience Co., Ltd. (2) · University Hospital, Basel, Switzerland (2)
United States (56) · China (19) · Spain (11) · Germany (9) · United Kingdom (9) · France (8) · Switzerland (8) · Canada (7) · Italy (6) · Australia (5) · Belgium (5) · Poland (5) · Russia (4) · Sweden (4) · Austria (3)
Harriet Kluger, MD (3) · Adil Daud, MD (2) · Jun Guo, MD (2) · Sarah Weiss, MD (2) · Agop Y. Bedikian, MD, BS (1) · Ahmad Tarhini, MD, PhD (1) · Albrecht Reichle, Professor (1) · Alfred Zippelius, Prof. (1) · Alice Y Zhou, M.D., Ph.D. (1) · Arielle Elkrief, MD (1) · Arina V Zinkina-Orikhan (1)
PMID 22426890, PMID 24695685, PMID 24844912, PMID 25252722, PMID 25369488, PMID 30689736, PMID 32523090, PMID 33294860, PMID 33914706, PMID 34140403, PMID 35190519, PMID 35193932, PMID 35596181, PMID 35867951, PMID 37964379, PMID 40338159, PMID 40580957, PMID 40721981, PMID 41606121, PMID 42847673
2023 (3), 2018 (2), U10CA180820 (2), 2019 (1), P30CA014089 (1), P30CA016056 (1), P30CA093373 (1), P50CA121974 (1), R01CA164333 (1), U10CA021115 (1), U10CA180888 (1)